Table 4 |
||||
| Relative expression of miR-21 and RECK in the malignant prostatic tissue in three profiles | ||||
|
↓miR-21 and ↓RECK |
↑miR-21 and ↓RECK |
↓miR-21 and ↑RECK |
P value | |
| Gleason Score | ||||
| < 7 | 56.0% | 33.3% | 31.3% | 0.215 |
| ≥ 7 | 44.0% | 67.7% | 68.7% | |
| Pathological Stage | ||||
| pT2 | 52.0% | 8.3% | 53.3% | 0.025 |
| pT3 | 48.0% | 91.7% | 46.7% | |
| PSA value | ||||
| <10 | 60.0% | 50.0% | 37.5% | 0.371 |
| ≥10 | 40.0% | 50.0% | 62.5% | |
| Biochemical Recurrence | ||||
| No | 75.0% | 36.4% | 50.0% | 0.087 |
| Yes | 25.0% | 63.6% | 50.0% | |
miR-21 and RECK underexpressed, miR-21 overexpressed and RECK underexpressed, and miR-21 underexpressed and RECK overexpressed, correlated either with Gleason score, pathological stage, PSA serum value or biochemical recurrence. Fold change in gene expression was calculated using the ΔΔCT method (QRel = 2-ΔΔCT).
Reis et al. BMC Urology 2012 12:14 doi:10.1186/1471-2490-12-14
